Sotyktu (deucravacitinib) / BMS - LARVOL DELTA

Comparison of Deucravacitinib and Adalimumab for the Treatment of Relapsed Takayasu’s Arteritis (ChiCTR) - P4 | N=50 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital; Peking Union Medical College Hospital

New P4 trial • Vasculitis

Successful Management of Multidrug-Resistant Psoriatic Arthritis Coexisting With Rheumatoid Arthritis Using a TYK2 Inhibitor Deucravacitinib-Based Regimen. (PubMed, J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • TYK2

Case Report: Effectiveness of deucravacitinib in chronic recurrent multifocal osteomyelitis and concomitant psoriasis. (PubMed, Front Immunol) - "During treatment with the tumor necrosis factor (TNF)-alpha inhibitor adalimumab, he developed severe palmoplantar psoriasis that affected his quality of life and necessitated discontinuation of the drug despite its efficacy against CRMO. Subsequent treatment with the interleukin (IL)-17a inhibitor secukinumab did not improve the psoriasis and led to a recurrence of the osteomyelitis...This resulted in clinical and morphological complete and sustained remission of CRMO within 12 weeks and a significant improvement of the psoriasis after six months of treatment with no occurrence of severe adverse events. To our knowledge, this is the first case report demonstrating complete and safe remission of CRMO associated with palmoplantar psoriasis treated with the TYK2 inhibitor deucravacitinib."

Journal • Dermatology • Immunology • Inflammation • Oncology • Psoriasis • TYK2

A cost-effectiveness analysis of deucravacitinib vs. apremilast in moderate-to-severe psoriasis patients in Japan. (PubMed, J Med Econ) - P3 | "Deucravacitinib is cost-effective compared to apremilast in patients with moderate-to-severe plaque psoriasis in Japan, primarily driven by improvements in health-related quality of life associated with a more favorable PASI response. This conclusion is supported by extensive sensitivity and scenario analyses."

HEOR • Journal • Dermatology • Immunology • Psoriasis

DELPHIN: A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany (clinicaltrials.gov) - P=N/A | N=550 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Recruiting ➔ Active, not recruiting | Trial primary completion date: Apr 2025 ➔ Aug 2025

Enrollment closed • HEOR • Trial primary completion date • Dermatology • Immunology • Psoriasis

DEUCRAVACITINIB IN PLAQUE PSORIASIS: IMMUNE RESPONSE TO AND SAFETY OF PNEUMOCOCCUS AND TETANUS TOXOID VACCINES IN THE POETYK LTE TRIAL (EULAR 2025) - P3 | "In patients with plaque psoriasis, continuing deucravacitinib treatment did not impact humoral immune responses to the PPSV-23 (T-cell independent) and TTV (T-cell dependent) vaccines. Our data suggest that withholding deucravacitinib treatment at the time of these vaccinations is not required."

Clinical • Dermatology • Discoid Lupus Erythematosus • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Pneumococcal Infections • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Sjogren's Syndrome • Systemic Lupus Erythematosus • Tetanus • TYK2

Efficacy and safety of deucravacitinib up to week 16 from POETYK PsA-1: a multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with active psoriatic arthritis (EULAR 2025) - P3 | "Treatment with deucravacitinib, the first oral TYK2 inhibitor evaluated in phase 3 studies of active PsA, resulted in superior efficacy vs placebo at W16 across multiple endpoints, including overall disease activity measures, musculoskeletal and dermatologic manifestations, and QoL in adults with active PsA who were naive to bDMARDs. Inhibition of radiographic progression was observed with deucravacitinib at W16 in post hoc analyses. Safety was consistent with the established safety profile of deucravacitinib in the phase 3 POETYK PsA-2 study, the phase 2 PsA study, and across the PsO clinical program,p [1, 2, 3, 4, 5] with no new safety signals identified."

Clinical • Late-breaking abstract • P3 data • Cardiovascular • Dermatology • Fatigue • Immunology • Infectious Disease • Inflammatory Arthritis • Musculoskeletal Diseases • Oncology • Psoriasis • Psoriatic Arthritis • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • CRP • TYK2

Impact of deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, on glucocorticoid use and flares in patients with active systemic lupus erythematosus: a post hoc analysis of the phase 2 PAISLEY trial (EULAR 2025) - P2, P3 | "The PAISLEY study design included a mandatory GC taper to ≤ 7.5 mg/day from weeks 8 to 20 for patients receiving a > 7.5-mg/day dose of prednisone or equivalent at baseline (taper-required population), a stable GC dose from weeks 20 to 32, an optional GC taper from weeks 32 to 40, and stable doses from weeks 40 to 48. This post hoc analysis of the PAISLEY trial demonstrated that deucravacitinib reduced GC dosing vs placebo by week 48. This effect was not offset by the need for GC rescue doses. A trend toward fewer moderate to severe flares was seen in patients treated with deucravacitinib vs placebo."

Clinical • P2 data • Retrospective data • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • TYK2

Investigating the impact of deucravacitinib treatment on cardiovascular risk-associated biomarkers in patients with systemic lupus erythematosus: results from the phase 2 PAISLEY study (EULAR 2025) - P2, P3 | "Patients with SLE had elevated CV risk-associated biomarkers at baseline compared with NHVs, and this effect was most apparent in those with a known history of CV disease. Baseline proteomic profiles also differed in patients with vs without a history of CV disease. Treatment with deucravacitinib resulted in improvements in some CV risk-associated biomarkers from baseline in the overall population of patients with SLE and in patients with a history of CV disease, while treatment with placebo did not result in changes in biomarker levels from baseline."

Biomarker • Clinical • P2 data • Cardiovascular • CNS Disorders • Congestive Heart Failure • Heart Failure • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Myocardial Infarction • Systemic Lupus Erythematosus • Vascular Neurology • GDF15 • JAK1 • JAK2 • TYK2

Deucravacitinib POETYK PsA and PsO clinical study data (EULAR 2025) - "Sponsored by BMS."

Clinical

BMS - TYK-ing the Path Forward in PsA (EULAR 2025) - "Sponsored by BMS. Learning Objectives:1) Discuss treatment challenges and unmet needs in patients with PsA.2) Highlight the latest scientific updates in PsA.3) Review the rationale for targeting the TYK2 pathway in PsA.4) Present phase 3 PsA data and long-term PsO data from the deucravacitinib POETYK clinical programs."

TYK2

Impact of deucravacitinib treatment on cardiovascular risk–associated scores and biomarkers in patients with active psoriatic arthritis: results from a phase 2 trial (EULAR 2025) - P2, P3 | "Covariates included age, baseline body mass index, baseline disease activity (Psoriasis Area Severity Index [PASI] score and Disease Activity Score 28 [DAS28]), previous tumor necrosis factor (TNF) inhibitor use, and previous methotrexate use. Our findings suggest that treatment with deucravacitinib may improve serologic CV risk scores and CV risk–associated biomarker levels in patients with PsA. Differential proteomic profiles were observed in patients with a history of HTN and among patients with higher ASCVD risk scores; deucravacitinib treatment led to either no change or numerical improvement of the associated biomarker levels. Further evaluation of these observations is warranted in a larger PsA patient population from the ongoing phase 3 POETYK PsA-1 (NCT04908202) and POETYK PsA-2 (NCT04908189) studies as well as in other rheumatologic conditions with increased CV risk."

Biomarker • Clinical • P2 data • Atherosclerosis • Cardiovascular • Dermatology • Hypertension • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL23A • JAK1 • TNFRSF1A • TYK2

Efficacy and safety of oral deucravacitinib in patients with cutaneous manifestations of lupus erythematosus: results from PAISLEY CLE, a global, randomized, placebo-controlled, phase 2 trial (EULAR 2025) - P2, P3 | "In patients with DLE and/or SCLE with or without SLE, statistically significant and clinically meaningful improvements were observed for the primary endpoint and different CLASI-A endpoints with deucravacitinib 3 mg and 6 mg BID vs placebo at week 16. Deucravacitinib was well tolerated, and AEs were consistent with the known safety profile. These data support further evaluation of deucravacitinib for the treatment of cutaneous manifestations of lupus, including in patients with SLE in the ongoing phase 3 POETYK SLE trials (NCT05617677, NCT05620407)."

Clinical • P2 data • Cardiovascular • Cutaneous Lupus Erythematosus • Dermatitis • Dermatology • Discoid Lupus Erythematosus • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Oncology • Pain • Psoriasis • Respiratory Diseases • Systemic Lupus Erythematosus • Varicella Zoster • Venous Thromboembolism • TYK2

Efficacy and safety of deucravacitinib up to week 52 from POETYK PsA-2: a multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with psoriatic arthritis (EULAR 2025) - P3 | "Patients were randomized 3:3:1 to deucravacitinib 6 mg once daily, placebo, or apremilast 30 mg twice daily (safety reference arm) through week 16. Deucravacitinib, the first oral TYK2 inhibitor evaluated in a phase 3 PsA study, showed superior efficacy vs placebo across multiple endpoints at week 16, including musculoskeletal and dermatologic manifestations, overall disease activity measures, and quality of life in adults with active PsA. Clinical responses were maintained through week 52. Safety was consistent with the established deucravacitinib safety profile observed in the phase 2 PsA study and across the PsO clinical program [1-4]; no new safety signals were identified."

Clinical • P3 data • Cardiovascular • Dermatology • Fatigue • Immunology • Infectious Disease • Inflammatory Arthritis • Musculoskeletal Diseases • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • CRP • TYK2

Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis (EULAR 2025) - "One patient experienced two mild upper respiratory infections (URIs) on bimekizumab and deucravacitinib, prompting a switch for risankizumab with deucravacitinib...We also identified 15 patients treated with bDMARDs combined with apremilast (APR) for a median duration of 735 days... Overall, the safety profile of bDMARD combinations with JAKi, TYK2i, and APR was favorable. Infections, primarily URIs, were the most commonly observed adverse events. All reported infections were mild, managed without hospitalization, and rarely led to therapy discontinuation."

Dental Disorders • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Musculoskeletal Diseases • Pain • Psoriasis • Psoriatic Arthritis • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Stomatitis • IL12A • IL17A

DEUCRAVACITINIB IN MODERATE TO SEVERE PLAQUE PSORIASIS: 5-YEAR, LONG-TERM SAFETY AND EFFICACY RESULTS FROM THE PHASE 3 POETYK PSO-1, PSO-2, AND LTE TRIALS (EULAR 2025) - P3 | " Patients were randomized 1:2:1 to oral placebo, deucravacitinib 6 mg once daily, or apremilast 30 mg twice daily. Deucravacitinib demonstrated a consistent safety profile through 5 years with no emergence of any new safety signals. Clinical efficacy rates were maintained through 5 years of continuous treatment with once-daily oral deucravacitinib. These data support the long-term safety and durable efficacy profile through 5 years of treatment with deucravacitinib, a first-in-class TYK2 inhibitor treatment for psoriasis."

Clinical • P3 data • Dermatology • Discoid Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Sjogren's Syndrome • Systemic Lupus Erythematosus • TYK2

Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors (EULAR 2025) - "Simulated plasma concentrations were above TYK2 IC 50 for 24 hours for zasocitinib 30 mg once daily (QD) versus 3 hours for deucravacitinib 6 mg QD, and 0 hours for baricitinib 4 mg QD, upadacitinib 30 mg QD and tofacitinib 10 mg twice daily (Figure 1). Selective TYK2 inhibition offers a distinct cytokine receptor associated proximal signal kinase inhibition profile. Zasocitinib showed greater and longer selective inhibition of TYK2-mediated signalling versus deucravacitinib at modelled comparative clinical dose, without affecting JAK1/3-mediated signalling."

Dermatology • Immunology • Psoriasis • IFNG • IL12A • IL2 • JAK1 • TYK2

Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis (clinicaltrials.gov) - P=N/A | N=25 | Not yet recruiting | Sponsor: Peking University First Hospital

New trial • Immunology • Psoriasis

Inhibition of TYK2 holds intrinsic and immune-mediated therapeutic potential in ALK-negative Anaplastic Large Cell Lymphoma (OeGHO-AHOP 2025) - "Since, we have previously demonstrated the importance of TYK2 in transgenic ALCL mouse models we hereby propose the TYK2 inhibitor Deucravacitinib as therapeutic option in this class of patients... Among ALCL types systemic ALCL, ALK- has the worst prognosis. We propose TYK2 and mTORC1 dual-inhibition as novel synergistic treatment avenue, particularly in ALCL, ALK- patients. Moreover, TYK2 inhibition promotes reactivation of patient’s anti-tumor immune response."

IO biomarker • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Systemic Anaplastic Large Cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • ANXA5 • CD163 • CD86 • STAT1 • STAT3 • TYK2

A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features (clinicaltrials.gov) - P=N/A | N=50 | Enrolling by invitation | Sponsor: Xi Tan

New trial • Real-world evidence • Atopic Dermatitis • Dermatology • Immunology • Psoriasis

The Sustainability of Week 16 Responses to Deucravacitinib Treatment for Patients With Psoriasis. (PubMed, J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Psoriasis

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial. (PubMed, Lupus Sci Med) - P2 | "Patients with SLE experienced greater improvements in pain, fatigue and health-related quality-of-life scores at week 48 with deucravacitinib versus placebo treatment."

Clinical • Journal • P2 data • Fatigue • Immunology • Inflammatory Arthritis • Lupus • Pain • Systemic Lupus Erythematosus • TYK2

Systematic review of comparative studies on emerging psoriasis treatments: comparing biologics with biologics, small molecule inhibitors with small molecule inhibitors, and biologics with small molecule inhibitors. (PubMed, Inflammopharmacology) - "This systematic review highlights the enhanced efficacy of IL-17 and IL-23 inhibitors compared to TNF-α inhibitors, with IL-23-targeting agents demonstrating superior long-term disease control. Small molecule inhibitors, particularly Deucravacitinib, present a promising alternative as effective oral therapies. Although newer biologics offer improved treatment outcomes, further head-to-head trials comparing TYK2, JAK, and PDE4 inhibitors with IL-17 and IL-23 agents are warranted. These findings provide valuable insights to inform clinical decision-making and optimise Psoriasis management strategies."

Journal • Review • Candidiasis • Dermatology • Immunology • Infectious Disease • Psoriasis • IL17A • IL23A • TYK2

Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms. (PubMed, Dermatol Ther (Heidelb)) - P3 | "Findings from this pooled analysis suggest that deucravacitinib may be used in patients with psoriasis to effectively treat both dermatologic and joint symptoms. Graphical abstract available for this article."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

A multi-action inhibitory mechanism of allosteric TYK2-specific inhibitors (SID 2025) - "Deucravacitinib is a highly selective allosteric inhibitor of protein tyrosine kinase 2 (TYK2)...This competitive binding directly prevents the formation of the active TYK2 state through steric clashes. Furthermore, we propose a structural mechanism that explains how phosphorylated STAT homo- and hetero-dimers are produced after activation during JAK-STAT signaling."

TYK2